Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: Evidence for primary azole prophylaxis

HIV Medicine

Volumn 6, Issue 4, 2005, Pages 253-259

  Cantey, Paul T ^a   Stephens, D S ^a   Rimland, D ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Azole; Cryptococcosis; HIV

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; FLUCONAZOLE; PYRROLE DERIVATIVE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CRYPTOCOCCOSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AZOLES; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCOSIS; HUMANS;

EID: 22644433301     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00289.x     Document Type: Article

References (40)

1. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17: 837-842.
2. Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 1985; 62: 475-495.
3. Hajjeh RA, Conn LA, Stephens DS et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999; 179: 449-454.
4. Perfect JR, Casadevall A. Cryptococcosis. Infect Dis Clin North Am 2000; 16: 837-874.
5. McNeil JI, Kan VL. Decline in the incidence of cryptococcosis among HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 206-208.
6. Hajjeh RA, Brandt ME, Pinner RW. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol Rev 1995; 17: 303-320.
7. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988; 157: 624-628.
8. Chuck SL, Sande AM. Infections with Cryptococcus neoformams in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321: 794-799.
9. Knudsen JD, Jensen L, Sørensen TL et al. Cryptococcosis in Denmark: an analysis of 28 cases in 1988-93. Scand J Infect Dis 1997; 29: 51-55.
10. Dromer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey (1985-93). Clin Infect Dis 1996; 23: 82-90.
11. Chen S, Sorrell T, Nimmo G et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 2000; 31: 499-508.
12. Sacktor N, Lyles RH, Skolasky R, Kleeberger C et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-98. Neurology 2001; 56: 257-260.
13. van Elden LJR, Walenkamp AME, Lipovsky MM et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000; 14: 2787-2788.
14. Dromer F, Mathoulin-Pélissier S, Fontanet A, Ronin O, Dupont B, Lortholary O. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 2004; 18: 555-562.
15. Holtzer CD, Jacobson MA, Hadley WK et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-97. AIDS 1998; 12: 1931-1933.
16. Oursler KAK, Moore RD, Chaisson RE. Risk factors for cryptococcal meningitis in HIV-infected patients. AIDS Res Hum Retroviruses 1999; 15: 625-631.
17. Quagliarello VJ, Viscoli C, Horowitz RI. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1995; 345: 548-552.
18. Sorvillo F, Beall G, Turner PA, Beer VL, Kovacs AA, Kerndt PR. Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. AIDS 1997; 11: 673-679.
19. Newton JA, Tasker SA, Bone WD et al. Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection. AIDS 1995; 9: 1286-1287.
20. Powderly WG, Finkelstein DM, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 700-705.
21. Feldmesser M, Harris C, Reichberg S, Khan S, Casadevall A. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis 1996; 23: 827-830.
22. Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002; 185: 1179-1182.
23. Vinhagool A, Sungkuanuparph S, Mootsikapun P et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective multi-center, randomized study. Clin Infect Dis 2003; 36: 1329-1331.
24. Mussino C, Pezzotti P, Miro JM et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004; 38: 565-571.
25. Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-98: regional variation and temporal trends. Clin Infect Dis 2001; 32: 955-962.
26. Bozzette SA, Berry SH, Duan N et al. The care of HIV-infected adults in the United States. N Engl J Med 1998; 339: 1897-1904.
27. Mirza SA, Phelan M, Rimland D et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance from 2 large metropolitan areas 1992-2000. Clin Infect Dis 2003; 36: 789-794.
28. Van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodefiency syndrome. New Engl J Med 1997; 337: 15-21.
29. Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83-89.
30. UNAIDS. Stepping Back from the Edge: the Pursuit of Antiretroviral Therapy in Botswana, South Africa, and Uganda. UNAIDS Best Practice Collection. Switzerland, Joint United Nations Programme on HIV/AIDS, 2003.
31. Centers for Disease Control and Prevention. Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons - 2002 Recommendations of the US Public Health Service and the Infectious Diseases Society of America. Morb Mortal Wkly Rep 2002; 51: 1-23.
32. Friese G, Discher T, Füssle R, Schmalreck A, Lohmeyer J. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 2001; 15: 2344-2345.
33. Berg J, Clancy CJ, Nguyen MH. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 1998; 26: 186-187.
34. Davey KG, Johnson EM, Holmes AD, Szekely A, Warnock DW. In-vitro susceptibility of Cryptococcus neoformans isolates to fluconzaloe and itraconazole. J Antimicrob Chemother 1998; 42: 217-220.
35. Brandt ME, Pfaller MA, Haijeh RA et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992-94 and 1996-98. Anitmicrob Agents Chemother 2001; 45: 3065-3069.
36. Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J Antimicrob Chemother 2003; 52: 683-686.
37. Chandenier J, Adou-Bryn KD, Douchet C et al. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis 2004; 23: 506-508.
38. Havlir DV, Dubé MP, McCutchan A et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998; 27: 1369-1375.
39. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med 2004; 5: 140-143.
40. Freedberg K, Schaferstein J, Seage G et al. The cost-effectiveness of preventing AIDS related opportunistic infections. J Am Med Assoc 1998; 279: 130-136.